Javascript must be enabled to continue!
Acute Opioid Administration Undermines Recovery after SCI: Adverse Effects Are Not Restricted to Morphine
View through CrossRef
Previous studies have shown that administration of high doses of morphine in the acute phase of spinal cord injury (SCI) significantly undermines locomotor recovery and increases symptoms of chronic pain in a rat spinal contusion model. Similarly, SCI patients treated with high doses of opioid for the first 24 h postinjury have increased symptoms of chronic pain 1 year later. Whether these adverse effects are driven by morphine only or all opioids compromise recovery after SCI, however, is unknown. Based on our previous findings we hypothesized that activation of the kappa opioid receptor (KOR) is key in the morphine-induced attenuation of locomotor recovery after SCI. Thus, we posited that opioids that engage KOR-mediated signaling pathways (morphine, oxycodone) would undermine recovery, and clinically relevant opioids with less KOR activity (fentanyl and buprenorphine) would not. To test this, we compared the effects of the clinically relevant opioids on locomotor recovery and pain in a male rat spinal contusion model. Rats were given a moderate spinal contusion injury followed by 7 days of intravenous morphine, oxycodone, fentanyl, buprenorphine, or saline, and recovery was assessed for 28 days. All opioids produced analgesia on tests of thermal, mechanical, and incremented shock reactivity. However, tolerance developed rapidly with buprenorphine administration, particularly with daily administrations of 5 morphine milligram equivalent (MME) buprenorphine. Opioid-induced hyperalgesia (OIH) also developed across days following administration of higher doses (10 MME, 20 MME) of morphine and oxycodone. Fentanyl and buprenorphine did not produce OIH. Contrary to our hypothesis, however, we found that high doses of all opioids reduced recovery of locomotor function. Unlike the other opioids, the effects of buprenorphine on locomotor recovery appeared transient, but it also produced chronic pain. Morphine, oxycodone, and buprenorphine decreased reactivity thresholds on tests of mechanical and incremented shock stimulation. In sum, all opioids undermined long-term recovery in the rat model. Further interrogation of the molecular mechanisms driving the adverse effects is essential. This study provides critical insight into pain management strategies in the acute phase of SCI and potential long-term consequences of early opioid administration.
Title: Acute Opioid Administration Undermines Recovery after SCI: Adverse Effects Are Not Restricted to Morphine
Description:
Previous studies have shown that administration of high doses of morphine in the acute phase of spinal cord injury (SCI) significantly undermines locomotor recovery and increases symptoms of chronic pain in a rat spinal contusion model.
Similarly, SCI patients treated with high doses of opioid for the first 24 h postinjury have increased symptoms of chronic pain 1 year later.
Whether these adverse effects are driven by morphine only or all opioids compromise recovery after SCI, however, is unknown.
Based on our previous findings we hypothesized that activation of the kappa opioid receptor (KOR) is key in the morphine-induced attenuation of locomotor recovery after SCI.
Thus, we posited that opioids that engage KOR-mediated signaling pathways (morphine, oxycodone) would undermine recovery, and clinically relevant opioids with less KOR activity (fentanyl and buprenorphine) would not.
To test this, we compared the effects of the clinically relevant opioids on locomotor recovery and pain in a male rat spinal contusion model.
Rats were given a moderate spinal contusion injury followed by 7 days of intravenous morphine, oxycodone, fentanyl, buprenorphine, or saline, and recovery was assessed for 28 days.
All opioids produced analgesia on tests of thermal, mechanical, and incremented shock reactivity.
However, tolerance developed rapidly with buprenorphine administration, particularly with daily administrations of 5 morphine milligram equivalent (MME) buprenorphine.
Opioid-induced hyperalgesia (OIH) also developed across days following administration of higher doses (10 MME, 20 MME) of morphine and oxycodone.
Fentanyl and buprenorphine did not produce OIH.
Contrary to our hypothesis, however, we found that high doses of all opioids reduced recovery of locomotor function.
Unlike the other opioids, the effects of buprenorphine on locomotor recovery appeared transient, but it also produced chronic pain.
Morphine, oxycodone, and buprenorphine decreased reactivity thresholds on tests of mechanical and incremented shock stimulation.
In sum, all opioids undermined long-term recovery in the rat model.
Further interrogation of the molecular mechanisms driving the adverse effects is essential.
This study provides critical insight into pain management strategies in the acute phase of SCI and potential long-term consequences of early opioid administration.
Related Results
Clinical pharmacology of morphine in infants and children
Clinical pharmacology of morphine in infants and children
Morphine is used to treat pain, for treatment of opioid dependence, and neonatal abstinence syndrome. Morphine is modestly absorbed from the gastrointestinal tract whereas after re...
Postoperative Opioid Consumption After Scheduled Compared With Unscheduled Cesarean Delivery
Postoperative Opioid Consumption After Scheduled Compared With Unscheduled Cesarean Delivery
OBJECTIVE:
To identify characteristics associated with high inpatient daily opioid consumption after cesarean delivery.
METHODS:
...
Comparing the safety and efficacy of intravenous naloxone administration in opioid-naive and opioid-tolerant hospitalized oncology patients
Comparing the safety and efficacy of intravenous naloxone administration in opioid-naive and opioid-tolerant hospitalized oncology patients
Objective: To compare naloxone doses and clinical outcomes after emergency opioid reversal in opioid-naïve and opioid-tolerant inpatients.Design: Cross-sectional, retrospective cha...
Morphine 6‐glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret
Morphine 6‐glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret
The emetic potencies of morphine and its metabolite morphine 6‐glucuronide have been determined in the ferret by constructing dose‐response curves for mean total retches and vomits...
CLIMATE-2019 Program committee
CLIMATE-2019 Program committee
NOTITLE. Chairman
Mokhov Igor
RAS academecian, Dr. Sci., Professor
...
Histone Deacetylase Inhibitors Prevented the Development of Morphine Tolerance by Decreasing IL6 Production and Upregulating μ-Opioid Receptors
Histone Deacetylase Inhibitors Prevented the Development of Morphine Tolerance by Decreasing IL6 Production and Upregulating μ-Opioid Receptors
Background:
Morphine tolerance on long-term usage leads to chronic pain conditions.
Preclinical studies demonstrated that the upregulation of HDACs is associated with a decrease in...
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
Abstract
Background
The United States is in the midst of an opioid overdose epidemic. We evaluated the temporal trends and risk...
Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats
Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats
Abstract
Background
Sleepiness and decrease in attention are dose-limiting side effects of opioids. The orexin/hypocretin...

